For Research Use Only


Euroclonality backdrop

Univ8 box

Why settle for less
when you can have it all?

Our first product, the EuroClonality-NDC assay allows you to detect immunoglobulin (IG) and T-cell receptor (TR) rearrangements and translocations, as well as mutations and copy number alterations in clinically relevant genes for most lymphoproliferative disorders.

EuroClonality-NDC has been designed and developed by the EuroClonality-NGS working group (an independent subdivision of EuroClonality) and validated in a multi-centre international study involving expert clinical and academic laboratories across Europe.

Univ8 Genomics & EuroClonality logo


Request a quotation

What our customers say

“We incorporated the EuroClonality-NDC assay for routine IG and TCR marker identification for MRD studies about a year ago. We have analysed more than 1000 samples so far and we are very happy with the results.” Prof. Monika Brüggemann from Kiel University, Germany
“The EuroClonality-NDC assay is a really convenient and useful tool for lymphoma testing. In our institution, we started with a pilot research project and after few months we incorporated it into routine use.” Dr Sarasquete and Dr Alcoceba, Salamanca University Hospital, Spain
“The EuroClonality-NDC assay offers and integrated and comprehensive assessment of the most important genomic aberrations required for routine diagnostic haematopathology practice, streamlining the request and reporting process. We can now simultaneously detect mutations, structural aberrations and assess clonality in FFPE specimens, achieving excellent correlation with legacy molecular tests. Since we incorporated the assay into our workflow, EuroClonality-NDC results have facilitated a more robust diagnosis in many cases, and in some cases have enabled diagnoses and distinctions that we were previously unable to render. This includes, for example, identifying emerging lymphoproliferations such as BCL3 translocated lymphomas, and distinguishing between plasmablastic myeloma and plasmablastic lymphoma. The failure rate of the assay is low and regularly obtain viable results on decalcified bone marrow specimens. Overall, we are delighted with the performance of the EuroClonality–NDC assay and thoroughly recommend it to other haematopathologists” Dr Matthew Pugh, Consultant Haematopathologist, Birmingham and Wales, UK

Composition of EuroClonality-NDC assay

The EuroClonality-NDC assay contains a series of genomic regions covering all the IG (including IGH switch regions) and TR genes, intronic regions of some commonly translocated genes, coding regions of clinically-relevant genes and specific regions for copy number variation (CNV) analysis.

List of genes with full coding regions mutation assessment on EuroClonality-NDC


List of genes with select regions for mutation assessment on EuroClonality-NDC

Gene NameRegion Covered
ABL1Exons 4-9
ASXL1Hotspot in last exon
BIRC3Exons 8 and 9
BRAFExons 11 and 15
CARD11Exons 2-16
CCND1Exon 1
CCND3Exon 5
CD79AExons 4 & 5
CD79BExons 4-6
CREBBPExons 2-30
CXCR4Hotspot in exon 2
DIS3Exons 1-3 and 9-18
DNMT3AExons 8-23
EGR2Hotspot in exon 2
EZH2Exons 15-17
FBXW7Exons 1-12
FOXO1Exon 1
IDH1Exon 4
IDH2Exons 4 and 7
IKZF1Exons 2-7
IL7RExon 6
IRF4Exons 2-3
JAK1Exons 12-15
JAK2Exons 12-15
JAK3Exons 11-24
KITExons 9, 11, 13, 17 and 18
KRASExons 2, 3 & 4
MAP2K1Exons 1-8
MEF2BExons 2-4
MYD88Exon 3-5
NOTCH1Exons 26, 27 & 34
NOTCH2Exon 34
NRASExons 2-4
NT5C2Exons 9-15
PIK3CAExons 2, 5 10 & 21
PLCG1Exons 1, 11, 15-17, 19 and 29
PLCG2Exons 19, 20 & 24
SF3B1Exons 12-17
STAT3Exons 10-16 and 20-21
STAT5BExons 13-19
STAT6Exons 5, 9, 11, 12 and 14
XPO1Exons 15-16

Additional Regions & Additional Chromosome Regions Assessed

Performance of the EuroClonality-NDC assay

The expected metrics for library preparation and hybridisation performance ensure sufficient coverage of all targets to obtain robust and reliable results.

Analytical sensitivity varies according to the type of alterations, from >95% for CNV up to >99% for sequence variants at >4% VAF. Analytical specificity also varies from >97% for CNV and IG/TR rearrangements up to >99% for sequence variants at >4% VAF.

Download Quick Reference and Analysis Guides

Expected metrics & Analytical Performance

EuroClonality-NDC CNV output for IG, TR and clinically relevant genes in cell line RS4;11

The EuroClonality-NDC assay produces copy number variant (CNV) outputs specifically for IG and TR rearrangements that can be used alongside the Rearrangement results to assess clonality in an orthogonal fashion. These CNV plots are most helpful when the tumour content is at least 40%. There is also an additional output (called ’Onco’) that shows CNV data across a range of clinically relevant genes and genomic regions included in the assay. CNV data have been validated for high molecular weight DNA samples containing more than 40% tumour cells.

Download examples of results produced by the EuroClonality-NDC assay
EuroClonality-NDC CNV for IG, TR and clinically relevant genes in cell line RS4;11
EuroClonality-NDC CNV for IG, TR and clinically relevant genes in cell line RS4;11
EuroClonality-NDC CNV for IG, TR and clinically relevant genes in cell line RS4;11

EuroClonality-NDC Copy number alteration plots in clinical samples

CNV plot for a CLL case showing trisomy 12 and a large deletion of 13q, with BCL2 gain
CNV plot for a CLL case showing 11q deletion and subclonal loss of the MDR in 13q
CNV plot for a CLL case showing focal TP53 and TRAF3 deletion
CNV plot for a myeloma case showing 13q deletion and gain of 1q (CKS1B), amongst other genomic alterations

Clinical and academic centres involved in the EuroClonality-NDC validation

Queen’s University BelfastBelfast, UK
Universitätsklinikum Schleswig-Holstein (UKSH)Kiel, GERMANY
CEITEC – Central European Technology InstituteBrno, CZECH REPUBLIC
The Royal Marsden NHS TrustLondon, UK
Centro Maria Letizia VergaMonza, ITALY
Hospital Universitario de SalamancaSalamanca, SPAIN
Hopital Necker-Enfants MaladesParis, FRANCE
Erasmus MC, university medical center RotterdamRotterdam, THE NETHERLANDS
Centre for Research and Technology HellasThessaloniki, GREECE
University of TorinoTorino, ITALY
Radboud university medical centre NijmegenNijmegen, THE NETHERLANDS
Hopital Pitié-SalpétrièreParis, FRANCE


We are building our portfolio of NGS solutions for you, working hard on expanding the clinical indications to give you the full Univ8 Genomics experience.

If you would like to be kept informed of our developments please subscribe here: